Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Methyl Aminolevulinate→

Methyl Aminolevulinate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
33320-16-0
Molecular formula
C6H11NO3
Molecular weight
145.16 g/mol
Drug class
Topical photosensitiserprodrug for photodynamic therapy
Mechanism of action
Methyl aminolevulinate is converted intracellularly to photoactive porphyrins, including protoporphyrin IX, which accumulate in treated skin lesions. After illumination with light of an appropriate wavelength in the presence of oxygen, these porphyrins generate singlet oxygen and other reactive oxygen species, causing phototoxic damage to target cells.
Indications / reported uses
  • Photodynamic treatment of actinic keratoses.
  • Photodynamic treatment of selected superficial basal cell carcinomas and Bowen’s disease, according to the authorised product label and illumination protocol.

Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d02af310-d097-4886-86e5-adcf6bca0533 · https://www.medicines.org.uk/emc/product/6777/smpc · https://register.awmf.org/assets/guidelines/032_D_Krebsgesellschaft/032-022OLeng_S3_Actinic-keratosis-and-squamous-cell-carcinoma-of-the-skin_2023-07.pdf · DailyMed

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical photosensitiser; prodrug for photodynamic therapy

Mechanism of action

Methyl aminolevulinate is converted intracellularly to photoactive porphyrins, including protoporphyrin IX, which accumulate in treated skin lesions. After illumination with light of an appropriate wavelength in the presence of oxygen, these porphyrins generate singlet oxygen and other reactive oxygen species, causing phototoxic damage to target cells.

General use cases

  • Photodynamic treatment of actinic keratoses.
  • Photodynamic treatment of selected superficial basal cell carcinomas and Bowen’s disease, according to the authorised product label and illumination protocol.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Methyl Aminolevulinate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Methyl Aminolevulinate Permitted Daily Exposure (PDE) report (the Methyl Aminolevulinate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Methyl Aminolevulinate Occupational Exposure Limit (OEL) report (the Methyl Aminolevulinate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.